The effects of ketoconazole on ziprasidone pharmacokinetics - A placebo-controlled crossover study in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 49, Issue SUPPL. 1, 2000, Pages 71-76

  Miceli, J J ^a   Smith, M ^b   Robarge, L ^a   Morse, T ^a   Laurent, A ^c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c NONE   (United States)

Author keywords

Interaction; Ketoconazole; Pharmacokinetics; Ziprasidone

Indexed keywords

KETOCONAZOLE; ZIPRASIDONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SYNCOPE; VERTIGO;

EID: 0034059620     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00156.x     Document Type: Article

References (17)

1. Prakash C, Kamel A, Anderson W, Fouda H. Characterization of metabolites of CP-88 059 in rat using HPLC/RAM/-ESI/MS/MS. Proceedings of the 42nd ASMS Conference on Mass Spectrometry and Allied Topics. Chicago, USA. 1994; 355.
2. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie DJ. Ziprasidone metabolism and cytochrome P450 isoforms. Biol Psychiatry 1997; 42: 40S.
3. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D. Identification of the major human liver cytochrome P450 isoform (s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000; 49(Suppl. 1): 35S-42S.
4. Wilner KD, Hansen RA, Folger CJ, Geoffroy P. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br J Clin Pharmacol 2000; 49(Suppl. 1): 57S-60S.
5. Muirhead GJ, Harness J, Holt PR, Oliver S, Anziano RJ. Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Br J Clin Pharmacol 2000; 49(Suppl. 1): 49S-56S.
6. Miceli JJ, Laurent A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol 2000; 49(Suppl. 1): 65S-70S.
7. Bennett JE. Antimicrobial agents: antifungal agents. In The Pharmacological Basis of Therapeutics, 9th edn, eds. Hardman JJG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A. USA. McGraw-Hill, 1996; 1175-1190.
8. Ament PW, Paterson A. Drug interactions with the non-sedating antihistamines. Am Fam Physician 1997; 56: 223-231.
9. Sadowski DC. Drug interactions with antacids. Mechanisms and clinical significance. Drug Safety 1994; 11: 395-407.
10. Metropolitan height and weight tables. Stat Bull Metrop Life Found 1983; 64: 3-9.
11. Janiszewski JS, Fouda HG, Cole RO. Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase excavation and narrow-bore high-performance liquid chromatography. J Chromatogr 1995; 668: 133-139.
12. Babe KS, Serafin WE. Histamine, bradykinin, and their antagonists. In The Pharmacological Basis of Therapeutics, 9th edn, eds. Hardman JJG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A. USA. McGraw-Hill, 1996; 581-600.
13. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57: 12-25.
14. Raeissi SD, Guo Z, Dobson GL, Artursson P, Hidalgo IJ. Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human Intestine. Pharm Res 1997; 14: 1019-1025.
15. Preskorn SH. Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. Caddo, OK, USA. Professional Communications, 1996.
16. Daneshmend TK, Warnock DW, Ene MD, et al. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother 1984; 25: 1-3.
17. Lelawongs P, Barone AB, Colaizzi JL, et al. Effects of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharmacol 1988; 7: 228-235.